Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer

BATON ROUGE, La., Dec. 07, 2018 (GLOBE NEWSWIRE) — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary…

About Globe Newswire

Nasdaq Globenewswire on NEWSTAGE
View all posts by Globe Newswire →